Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 42365246

Potential evaluation of SULT1A3 as an early diagnostic marker for nasopharyngeal carcinoma: a study based on serum proteomics screening and ELISA validation.

Zhifang Lin·Wei Song·Wenhai Liang·Jian Liu·Ruiwei Gan·Yueying Wang
View original source ↗Export metadata ↓

Abstract

BACKGROUND: Nasopharyngeal carcinoma (NPC) represents a highly prevalent and aggressive malignancy endemic to Southeast Asia. Early and accurate diagnosis is critical to improving survival outcomes; however, the absence of robust, stage-specific biomarkers remains a key obstacle to clinical implementation of early screening strategies. METHODS: We performed untargeted serum proteomic profiling using mass spectrometry in 15 treatment-na&#xef;ve early-stage NPC patients and 15 VCA-IgA-positive healthy controls. Bioinformatics analyses were conducted to identify differentially expressed proteins (DEPs). Machine learning (random forest combined with recursive feature elimination) was employed to prioritize candidate biomarkers, which were subsequently verified using enzyme-linked immunosorbent assay (ELISA) in independent sample cohorts. RESULTS: In total, 1,428 serum proteins were identified, among which 1,410 were reliably quantified. We observed 31 upregulated and 189 downregulated proteins in NPC patients relative to controls. Spearman correlation analysis revealed significant associations: LTA4H (leukotriene A4 hydrolase) levels correlated with serum cell infiltration (r&#x2009;=&#x2009;0.383, p&#x2009;=&#x2009;0.032) and CD8&#x2009;+&#x2009;T-cell abundance (r&#x2009;=&#x2009;0.408, p&#x2009;=&#x2009;0.021); both SULT1A3 (sulfotransferase family 1&#xa0;A member 3) and FGL1 (fibrinogen-like protein 1) levels were positively associated with M1 macrophage infiltration (r&#x2009;=&#x2009;0.510, p&#x2009;=&#x2009;0.003 and r&#x2009;=&#x2009;0.430, p&#x2009;=&#x2009;0.015, respectively). In a preliminary validation cohort (n&#x2009;=&#x2009;80), ELISA yielded AUC values of 0.631 (95% CI: 0.515-0.736, p&#x2009;=&#x2009;0.04) for LTA4H, 0.787 (95% CI: 0.681-0.871, p&#x2009;<&#x2009;0.001) for SULT1A3, and 0.688 (95% CI: 0.575-0.787, p&#x2009;=&#x2009;0.002) for FGL1. In large-scale independent validation, SULT1A3 achieved an AUC of 0.826 (95% CI: 0.766-0.876; sensitivity&#x2009;=&#x2009;78.89%, specificity&#x2009;=&#x2009;75.47%) in cohort 1 (n&#x2009;=&#x2009;196) and 0.796 (95% CI: 0.723-0.857; sensitivity&#x2009;=&#x2009;76.67%, specificity&#x2009;=&#x2009;76.67%) in cohort 2 (n&#x2009;=&#x2009;150). CONCLUSIONS: Through an integrated workflow combining proteomic screening, machine learning prioritization, and multi-stage ELISA validation, we identified SULT1A3 as a candidate serum-based biomarker for early detection of NPC. Preliminary findings suggest that SULT1A3 may have potential utility in clinical screening, though further validation in independent, multi&#x2011;center cohorts is required.

Explore related subjects

HumansBiomarkers, TumorFemaleProteomicsEnzyme-Linked Immunosorbent AssayNasopharyngeal CarcinomaMaleEarly Detection of CancerNasopharyngeal NeoplasmsMiddle AgedAdultArylsulfotransferaseCase-Control StudiesROC CurveBiomarkerEarly diagnosisMachine learningNPCSerum proteomicsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Zhifang Lin, Wei Song, Wenhai Liang, Jian Liu, Ruiwei Gan, Yueying Wang. 2026-06-27. Potential evaluation of SULT1A3 as an early diagnostic marker for nasopharyngeal carcinoma: a study based on serum proteomics screening and ELISA validation.. https://doi.org/10.1186/s12885-026-16428-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2027

Global Genomic Surveillance.

Global genomic surveillance has emerged as a foundational pillar of public health in the twenty-first century, enabling real-time tracking of pathogen evolution and informing outbreak response. This chapter examines the strategic architecture of global genomic surveillance, focusing on its application to arboviruses such as chikungunya virus (CHIKV). It explores the integration of genomic data with epidemiological, clinical, and environmental information within a One Health framework, while addressing critical challenges in governance, equity, and interoperability. The discussion covers the entire genomic surveillance workflow, from sample collection and sequencing to bioinformatic analysis and phylogenetic inference, and highlights the transformative role of artificial intelligence (AI) in predictive surveillance. By analyzing global initiatives, operational barriers, and emerging technologies, this chapter underscores the necessity of sustainable, equitable, and interoperable genomic systems to proactively address current and future infectious disease threats.

Humans↗
PubMed2027

Systematic Dissection of Key Driver Perturbation Signatures in Single Cells via ECCITE-seq.

CRISPR screens, such as expanded CRISPR-compatible cellular indexing of transcriptomes and epitopes by sequencing (ECCITE-seq), enable the simultaneous measurement of transcriptomes, gRNA identity, and cell-surface protein expression at single-cell resolution to systematically interrogate gene function. This platform provides a powerful and scalable experimental approach for validating disease-associated regulators identified by large-scale association studies and other computational methods, including network-based analyses of multi-omics data. Here, as an example application, we describe an ECCITE-seq framework to characterize the transcriptomic consequences of perturbing multiple neuronal key driver genes associated with Alzheimer's disease (AD) in human-induced pluripotent stem cell (hiPSC)-derived neurons. More broadly, by integrating customized pooled gRNA libraries with different CRISPR effectors across multiple cell types, this approach allows for the assessment of the regulatory impact of candidate genes implicated in development and disease processes.

Humans↗
PubMed2027

Identification of Genome-Wide Chromatin Structural Aberration in Cancer by Hi-C Analysis.

Aberrant three-dimensional genome organization is a hallmark of cancer, often driving oncogene activation through mechanisms such as enhancer hijacking. High-throughput chromosome conformation capture (Hi-C) maps these interactions on a genome-wide scale. Unlike earlier dilution-based methods, in situ Hi-C performs proximity ligation within intact nuclei, minimizing random ligation noise and enabling fine-scale structure detection. This chapter describes an optimized in situ Hi-C protocol tailored for cancer cell lines using MboI digestion and biotin-mediated pull-down to generate high-complexity libraries. We further outline a computational workflow that extends beyond standard topological mapping of compartments and topologically associating domains to identify cancer-specific aberrations. Specifically, we focus on detecting chromosomal rearrangements (structural variants) and characterizing the distinct circular topology of extrachromosomal DNA. This integrated experimental and analytical framework provides the necessary tools to dissect the spatial dysregulation underlying tumor evolution.

Humans↗